Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

This part is based on the following publication:

Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

Part II: Prostate Cancer

The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Part III: Apoptosis

The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.

This part is based on the following publication:

Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies? pipeline and portfolio planning (PPP) in cancer by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
• Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug?s properties
• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
• Supporting development of integrative molecule, pathway and disease area strategies
• Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Source: http://c.moreover.com/click/here.pl?r5684239807&f=378

bobolink breeders cup hamilton park brian wilson freedom writers lemony snicket lemony snicket